Korro Bio, Inc. (KRRO) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing genetic medicines through its OPERA RNA-editing platform, with lead programs in hyperammonemia and alpha-1 antitrypsin deficiency. On Monday morning, the stock traded at $13.20, down $0.41, or 3.01%, from Friday's closing price of $13.61. The direction is unambiguously lower. No verified company-specific catalyst — no press release, SEC filing, or analyst revision — was published before the move, and the decline appears to be a continuation of selling pressure that has been building since the start of the month.
No verified news or fundamental catalyst found for Monday's decline. The company's most recent disclosures were routine: an inducement grant under Nasdaq Listing Rule 5635(c)(4) announced on November 13, and a Form 4 reporting a director's sale of roughly 66,600 shares — about $973,000 — executed on November 11 and 12 under a pre-arranged 10b5-1 plan adopted in April 2026. Neither constitutes a material operating event. The most plausible assessment is that this is a technical unwind rather than a news-driven repricing, consistent with the stock's recent pattern: KRRO rallied roughly 96% from its October 16 close of $8.49 to a November 4 close of $16.62, then gave back about 21% through Monday's print. In a name with a float near 8.6 million shares and a beta of 2.07, moves of 3% happen routinely — this one carried no outsized volume to suggest institutional repositioning.
The one genuine fundamental development of the past two weeks was Novo Nordisk's November 3 notice terminating the companies' research collaboration and license agreement, effective February 1, 2027. Korro disclosed the termination alongside third-quarter results, with roughly $7.8 million of remaining deferred revenue now expected to be recognized in the fourth quarter of 2026. Collaboration revenue was already zero in the third quarter, so the change removes future milestones and royalties rather than existing income — which is why the initial reaction was severe (an 11.4% drop on November 5) but not existential. The company ended the quarter with $124.8 million in cash, equivalents, and marketable securities, a runway management expects to fund operations into the second half of 2028. That termination is background pressure, not Monday's trigger; it was fully public eleven days before this session.
Volume in recent sessions has run well below the three-month average of roughly 180,000 shares, and Monday's early turnover showed no sign of capitulation-style activity. The decline was directionally in line with the sector but larger in magnitude: the small-cap biotech benchmark fell about 1.1% and the large-cap biotech benchmark about 0.8%, so KRRO's high-beta profile amplified a modest sector drift rather than diverging on idiosyncratic news. Notably, Novo Nordisk traded higher on the day, ruling out any read-through from the former partner. Technically, the shares slipped below their 20-day moving average near $13.50 but remain comfortably above the 50-day average at $11.86 and the 200-day average at $12.17, having traded as high as $17.35 and as low as $5.20 over the past year. With a market capitalization of about $181 million, the stock remains nearly 24% below its early-November peak but roughly 55% above its October low.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. KRRO earns 12 out of 100. The verified news backdrop is thin and old: a terminated collaboration already digested, a routine inducement grant, and a scheduled insider sale under a pre-set plan. Judged against a roughly $181 million market capitalization, none of that is material to intrinsic value. The price behavior was equally unremarkable — Monday's 3.01% decline is about 0.75 times the stock's average absolute daily move of roughly 4% over the past 70 sessions, and moves of 3% or more occurred 32 times in that window. Weak news and an ordinary move combine into a low score.
The next scheduled financial update is the fourth-quarter and full-year 2026 report, expected early in 2027, and management has also flagged a presentation at the Jefferies Global Healthcare Conference in London. Operationally, investors are focused on the Phase 1/2 ANCHOR trial of KRRO-121: Part 1 single- and multiple-ascending-dose work in healthy volunteers is enrolling, patient dosing in urea cycle disorders is targeted for the first half of 2027 pending regulatory clearance, and an interim clinical readout is guided for the second half of 2027. A regulatory submission for KRRO-111 in alpha-1 antitrypsin deficiency is planned for the first half of 2027. Analyst consensus remains a Strong Buy with an average target near $21.50, though ratings are dispersed — RBC carries a Hold with a $10 target, while Citi and H.C. Wainwright are constructive. Key risks include the absence of any collaboration revenue, continued cash burn, dilution risk, and the possibility that clinical timelines slip.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions, drawn from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy logic, holding period, performance metrics, and the symbols they trade, which makes the trending list a practical starting point for comparing approaches side by side. Volatile small-cap names like this one often surface there. Readers looking for systematic, rules-based exposure may find it worth a closer look.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for KRRO moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 27 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRRO as a result. In 71 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for KRRO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
KRRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.592). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology